IL191271A - Pharmaceuticals for the treatment of dry eye conditions containing adenocin 3a receptor agonist - Google Patents

Pharmaceuticals for the treatment of dry eye conditions containing adenocin 3a receptor agonist

Info

Publication number
IL191271A
IL191271A IL191271A IL19127108A IL191271A IL 191271 A IL191271 A IL 191271A IL 191271 A IL191271 A IL 191271A IL 19127108 A IL19127108 A IL 19127108A IL 191271 A IL191271 A IL 191271A
Authority
IL
Israel
Prior art keywords
dry eye
adenosine
meca
eye
iodobenzyl
Prior art date
Application number
IL191271A
Other languages
English (en)
Hebrew (he)
Other versions
IL191271A0 (en
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Priority to IL191271A priority Critical patent/IL191271A/en
Publication of IL191271A0 publication Critical patent/IL191271A0/en
Publication of IL191271A publication Critical patent/IL191271A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
IL191271A 2006-01-27 2008-05-06 Pharmaceuticals for the treatment of dry eye conditions containing adenocin 3a receptor agonist IL191271A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL191271A IL191271A (en) 2006-01-27 2008-05-06 Pharmaceuticals for the treatment of dry eye conditions containing adenocin 3a receptor agonist

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76250606P 2006-01-27 2006-01-27
PCT/IL2006/000130 WO2007086044A1 (en) 2006-01-27 2006-02-01 Adenosine a3 receptor agonists for the treatment of dry eye disorders
IL191271A IL191271A (en) 2006-01-27 2008-05-06 Pharmaceuticals for the treatment of dry eye conditions containing adenocin 3a receptor agonist

Publications (2)

Publication Number Publication Date
IL191271A0 IL191271A0 (en) 2009-08-03
IL191271A true IL191271A (en) 2014-03-31

Family

ID=36794417

Family Applications (1)

Application Number Title Priority Date Filing Date
IL191271A IL191271A (en) 2006-01-27 2008-05-06 Pharmaceuticals for the treatment of dry eye conditions containing adenocin 3a receptor agonist

Country Status (9)

Country Link
EP (1) EP1976494A1 (ja)
JP (2) JP5185139B2 (ja)
KR (1) KR101037095B1 (ja)
CN (1) CN101365430B (ja)
AU (1) AU2006336834B2 (ja)
BR (1) BRPI0621052A2 (ja)
CA (1) CA2622975C (ja)
IL (1) IL191271A (ja)
WO (1) WO2007086044A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2137202B1 (en) 2007-03-14 2017-06-21 Can-Fite Biopharma Ltd. Process for the synthesis of ib-meca
IL184620A0 (en) * 2007-07-15 2008-01-20 Can Fite Biopharma Ltd Composition for the treatment of inflammation
WO2010014921A2 (en) 2008-08-01 2010-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
AU2009231978C1 (en) 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
US8557790B2 (en) 2009-05-17 2013-10-15 Can-Fite Biopharma Ltd. A3 adenoside receptor agonists for the reduction of intraocular pressure

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
WO2004029025A2 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of autoimmune disorders using clofarabine
WO2005121320A1 (ja) * 2004-06-10 2005-12-22 Kyowa Hakko Kogyo Co., Ltd. 幹細胞自己複製促進剤
ES2432113T3 (es) * 2004-07-28 2013-11-29 Can-Fite Biopharma Ltd. Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren

Also Published As

Publication number Publication date
JP2013032396A (ja) 2013-02-14
KR20080090517A (ko) 2008-10-08
CA2622975A1 (en) 2007-08-02
CN101365430A (zh) 2009-02-11
BRPI0621052A2 (pt) 2012-07-17
IL191271A0 (en) 2009-08-03
JP2009524647A (ja) 2009-07-02
KR101037095B1 (ko) 2011-05-26
AU2006336834B2 (en) 2009-12-10
JP5185139B2 (ja) 2013-04-17
CA2622975C (en) 2011-05-03
CN101365430B (zh) 2011-09-21
WO2007086044A1 (en) 2007-08-02
EP1976494A1 (en) 2008-10-08
AU2006336834A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
US7825102B2 (en) Treatment of dry eye conditions
EP1778239B1 (en) Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome
CA2622975C (en) Adenosine a3 receptor agonists for the treatment of dry eye disorders
DK2614838T3 (en) Diquafosol and hyaluronic acid or salts thereof for the treatment of dry eyes
JP2013166789A (ja) 骨関節炎の治療におけるａ３アデノシン受容体アゴニストの使用
US20080051364A1 (en) Therapeutic Treatment of Accelerated Bone Resorption
AU2005302090A1 (en) Therapeutic treatment of accelerated bone resorption
MX2008009506A (en) Adenosine a3 receptor agonists for the treatment of dry eye disorders
AU2010250759B2 (en) A3 adenosine receptor agonists for the reduction of intraocular pressure
US20130045943A1 (en) A3ar agonists for the treatment of uveitis
Shichijo et al. Agent for treatment of dry eye characterized by combining P2Y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the P2Y2 receptor agonist and hyaluronic acid or salt thereof
ITRM20000448A1 (it) Uso di un'associazione di vitamine per il trattamento delle cefalee primarie.

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees